| http://dbpedia.org/ontology/abstract
|
VIR-576 is an experimental drug that is un … VIR-576 is an experimental drug that is under clinical trials for the treatment of HIV-1 infections. VIR-576 is synthetic peptide that binds to HIV-1's hydrophobic fusion peptide gp41, preventing the virus from inserting itself into a host cell's membrane to initiate an infection. This drug is a synthesized variant of a highly specific natural entry inhibitor designated as (virus-inhibitory peptide). The design of VIR-576 was based on VIRIP which in turn was discovered in 2007 by and coworkers. This product is being developed by VIRO Pharmaceuticals GmbH & Co. KG.by VIRO Pharmaceuticals GmbH & Co. KG.
|
| http://dbpedia.org/ontology/pubchem
|
16729392
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/VIR-576_3D.gif?width=300 +
|
| http://dbpedia.org/ontology/wikiPageID
|
40869601
|
| http://dbpedia.org/ontology/wikiPageLength
|
17160
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1109790347
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Fluorenylmethyloxycarbonyl_chloride +
, http://dbpedia.org/resource/Host_cell +
, http://dbpedia.org/resource/Peptide_bonds +
, http://dbpedia.org/resource/Protease_inhibitor_%28pharmacology%29 +
, http://dbpedia.org/resource/Gp-41 +
, http://dbpedia.org/resource/CD4 +
, http://dbpedia.org/resource/Glycoprotein +
, http://dbpedia.org/resource/Lyophilization +
, http://dbpedia.org/resource/CXCR4 +
, http://dbpedia.org/resource/CCR5 +
, http://dbpedia.org/resource/HIV-1 +
, http://dbpedia.org/resource/T_helper_cell +
, http://dbpedia.org/resource/Category:Peptides +
, http://dbpedia.org/resource/Hydrogen_bonds +
, http://dbpedia.org/resource/Frank_Kirchhoff +
, http://dbpedia.org/resource/Hereditary_hyperbilirubinemia +
, http://dbpedia.org/resource/Category:Entry_inhibitors +
, http://dbpedia.org/resource/Cystine +
, http://dbpedia.org/resource/Peptide +
, http://dbpedia.org/resource/Gp41 +
, http://dbpedia.org/resource/T4_cell +
, http://dbpedia.org/resource/Solid-phase_synthesis +
, http://dbpedia.org/resource/Serine +
, http://dbpedia.org/resource/Antiretroviral_drug +
, http://dbpedia.org/resource/Mannitol +
, http://dbpedia.org/resource/Sifurtivide +
, http://dbpedia.org/resource/File:HIV-1MARAV.png +
, http://dbpedia.org/resource/VIRIP +
, http://dbpedia.org/resource/File:HIV-1_interaction_with_CD4_receptor_of_a_Th_human_lymphocyte.gif +
, http://dbpedia.org/resource/Alpha_1-antitrypsin +
, http://dbpedia.org/resource/Cysteine +
, http://dbpedia.org/resource/Matrix_metalloproteinases +
, http://dbpedia.org/resource/Enfuvirtide +
, http://dbpedia.org/resource/Fusion_inhibitor +
, http://dbpedia.org/resource/Gp120 +
, http://dbpedia.org/resource/Methionine +
, http://dbpedia.org/resource/Maraviroc +
, http://dbpedia.org/resource/Entry_inhibitor +
, http://dbpedia.org/resource/Retrovirus +
, http://dbpedia.org/resource/Antiretroviral +
|
| http://dbpedia.org/property/align
|
right
, center
|
| http://dbpedia.org/property/atcPrefix
|
J05
|
| http://dbpedia.org/property/atcSuffix
|
AX
|
| http://dbpedia.org/property/c
|
224
|
| http://dbpedia.org/property/caption
|
VIR-576 3D
|
| http://dbpedia.org/property/chemspiderid
|
20561003
|
| http://dbpedia.org/property/footer
|
Comparison between VIRIP and VIR-576 primary structures
, Appearance of the secondary structures of VIRIP and VIR-576
|
| http://dbpedia.org/property/h
|
322
|
| http://dbpedia.org/property/image
|
VIR-576 secondary structure.png
, Estructura virip.png
, Estructura vir576.png
, VIRIP secondary structure.png
|
| http://dbpedia.org/property/legalStatus
|
Under clinical trials
|
| http://dbpedia.org/property/n
|
42
|
| http://dbpedia.org/property/niaidChemdb
|
472841
|
| http://dbpedia.org/property/o
|
51
|
| http://dbpedia.org/property/pregnancyCategory
|
Unknown
|
| http://dbpedia.org/property/pubchem
|
16729392
|
| http://dbpedia.org/property/s
|
2
|
| http://dbpedia.org/property/smiles
|
CC[C@H][C@H]1CN2CCC[C@H]2CN[C@@H]CN[C@@H]CN[C@@H]CN1CCC[C@H]1CN1CCC[C@H]1CN[C@@H]CN[C@@H]CN[C@@H]CN[C@@H]CNCCN[C@@H]CN1CCC[C@H]1CN[C@@H]CN[C@@H]CN[C@@H]CO
|
| http://dbpedia.org/property/stdinchi
|
1
|
| http://dbpedia.org/property/stdinchikey
|
QMLQPHUSDUODMB-MFQMBSFASA-N
|
| http://dbpedia.org/property/width
|
283
, 320
, 500
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Cn +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Multiple_image +
, http://dbpedia.org/resource/Template:Drugbox +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Entry_inhibitors +
, http://dbpedia.org/resource/Category:Peptides +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Drug +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/VIR-576?oldid=1109790347&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Estructura_vir576.png +
, http://commons.wikimedia.org/wiki/Special:FilePath/Estructura_virip.png +
, http://commons.wikimedia.org/wiki/Special:FilePath/VIRIP_secondary_structure.png +
, http://commons.wikimedia.org/wiki/Special:FilePath/HIV-1MARAV.png +
, http://commons.wikimedia.org/wiki/Special:FilePath/VIR-576_3D.gif +
, http://commons.wikimedia.org/wiki/Special:FilePath/VIR-576_secondary_structure.png +
, http://commons.wikimedia.org/wiki/Special:FilePath/HIV-1_interaction_with_CD4_receptor_of_a_Th_human_lymphocyte.gif +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/VIR-576 +
|
| owl:sameAs |
http://dbpedia.org/resource/VIR-576 +
, https://global.dbpedia.org/id/Xwcj +
, http://yago-knowledge.org/resource/VIR-576 +
, http://sr.dbpedia.org/resource/VIR-576 +
, http://www.wikidata.org/entity/Q15410172 +
, http://sh.dbpedia.org/resource/VIR-576 +
, http://rdf.freebase.com/ns/m.0ynzq61 +
|
| rdf:type |
http://dbpedia.org/class/yago/Part113809207 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/class/yago/Peptide114743046 +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/class/yago/Compound114818238 +
, http://dbpedia.org/class/yago/Chemical114806838 +
, http://dbpedia.org/class/yago/Substance100019613 +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://dbpedia.org/class/yago/OrganicCompound114727670 +
, http://dbpedia.org/class/yago/Material114580897 +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
, http://www.wikidata.org/entity/Q8386 +
, http://dbpedia.org/class/yago/Abstraction100002137 +
, http://dbpedia.org/class/yago/WikicatPeptides +
, http://dbpedia.org/class/yago/Amide114724264 +
, http://dbpedia.org/class/yago/Relation100031921 +
|
| rdfs:comment |
VIR-576 is an experimental drug that is un … VIR-576 is an experimental drug that is under clinical trials for the treatment of HIV-1 infections. VIR-576 is synthetic peptide that binds to HIV-1's hydrophobic fusion peptide gp41, preventing the virus from inserting itself into a host cell's membrane to initiate an infection. This drug is a synthesized variant of a highly specific natural entry inhibitor designated as (virus-inhibitory peptide). The design of VIR-576 was based on VIRIP which in turn was discovered in 2007 by and coworkers. This product is being developed by VIRO Pharmaceuticals GmbH & Co. KG.by VIRO Pharmaceuticals GmbH & Co. KG.
|
| rdfs:label |
VIR-576
|
